N/A
Manufactured by Advagen Pharma Ltd
52,863 FDA adverse event reports analyzed
Last updated: 2026-04-14
LITHIUM BROMATUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Advagen Pharma Ltd. The most commonly reported adverse reactions for LITHIUM BROMATUM include DRUG INEFFECTIVE, TOXICITY TO VARIOUS AGENTS, OFF LABEL USE, DRUG INTERACTION, TREMOR. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LITHIUM BROMATUM.
Out of 24,361 classified reports for LITHIUM BROMATUM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 52,863 FDA FAERS reports that mention LITHIUM BROMATUM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, TOXICITY TO VARIOUS AGENTS, OFF LABEL USE, DRUG INTERACTION, TREMOR, NAUSEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Advagen Pharma Ltd in connection with LITHIUM BROMATUM. Always verify the specific product and NDC with your pharmacist.